The Korea Times close
National
  • Politics
  • Foreign Affairs
  • Multicultural Community
  • Defense
  • Environment & Animals
  • Law & Crime
  • Society
  • Health & Science
Business
  • Tech
  • Bio
  • Companies
Finance
  • Companies
  • Economy
  • Markets
Opinion
  • Editorial
  • Columns
  • Thoughts of the Times
  • Cartoon
  • Today in History
  • Blogs
  • Tribune Service
  • Blondie & Garfield
  • Letter to President
  • Letter to the Editor
Lifestyle
  • Travel & Food
  • Trends
  • People & Events
  • Books
  • Around Town
  • Fortune Telling
Entertainment
& Arts
  • K-pop
  • Films
  • Shows & Dramas
  • Music
  • Theater & Others
Sports
World
  • SCMP
  • Asia
Video
  • Culture
  • People
  • News
Photos
  • Photo News
  • Darkroom
  • The Korea Times
  • search
  • Site Map
  • E-paper
  • Subscribe
  • Register
  • LogIn
search close
  • The Korea Times
  • search
  • Site Map
  • E-paper
  • Subscribe
  • Register
  • LogIn
search close
Business
Bio
  • Tech
  • Bio
  • Companies
Wed, June 29, 2022 | 03:02
SK Bioscience COVID-19 vaccine closer to final approval
SK Bioscience COVID-19 vaccine closer to final approval
SK Bioscience has moved one step closer toward rolling out Korea's first COVID-19 vaccine, as the government advisory panel of pharmaceutical experts determined that a license for the use of the vaccine can be granted, according to the Ministry of Food and Drug Safety (MFDS), Monday. “The COVID-19 vaccine developed by SK Bioscience is the first COVID-19 vaccine produced in Ko...
Baek Byung-yeul | 2022-06-27 15:32
[INTERVIEW] Embracing routine PCR test is key to preventing next virus: Seegene CEO
[INTERVIEW] Embracing routine PCR test is key to preventing next virus: Seegene CEO
It's the middle of June and there is a chance that the country's new COVID-19 cases will surge again because of a rise in Omicron sub-variants currently being detected in the U.S. and Europe. The U.S. recently lifted its mandatory COVID testing for overseas travelers arriving by plane, which means that visitors no longer need to show negative test results or proof of recovery...
Kim Yoo-chul | 2022-06-16 12:34
SK Bioscience to test own COVID vaccine as booster
SK Bioscience to test own COVID vaccine as booster
SK Bioscience is set to conduct Phase 3 clinical trials of its COVID-19 vaccine in overseas countries to check its effectiveness as a booster shot. The biotech company also expects its vaccine could be approved by a health agency here, according to a company official, Monday.
Baek Byung-yeul | 2022-06-06 16:38
[INTERVIEW] Korea should strengthen ecosystem for clinical trials
[INTERVIEW] Korea should strengthen ecosystem for clinical trials
Over the last few years, the government has been supporting its strategy to help the country rise as a biotechnology hub in Asia given Korea's long-time competiveness in product manufacturing. The country's advantages in terms of having excellent infrastructure, workforce and IT platform have truly been beneficial amid COVID-19 as a number of biotechnology companies, includin...
Kim Yoo-chul | 2022-06-02 15:24
Samsung Biologics establishes one-stop mRNA vaccine production capability at Songdo plant
Samsung Biologics establishes one-stop mRNA vaccine production capability at Songdo plant
Samsung Biologics, the biotech arm of Korea's Samsung Group, has established a one-stop production capability for manufacturing messenger RNA (mRNA) vaccines by newly adding an mRNA vaccine substance production facility at the plant, a company official said Thursday.
2022-06-02 11:21
[INTERVIEW] Immunomic Therapeutics CEO expects meaningful test results for brain tumor drug
[INTERVIEW] Immunomic Therapeutics CEO expects meaningful test results for brain tumor drug
William Hearl, CEO of Immunomic Therapeutics, the U.S. subsidiary of the Korean biotech company, HLB, said that the company expects meaningful test results from its Phase 2 clinical trials of a drug for glioblastoma by August of this year at the latest.
Baek Byung-yeul | 2022-05-26 16:03
HLB gets positive Phase 3 data with liver cancer treatment
HLB gets positive Phase 3 data with liver cancer treatment
HLB has taken a step closer to the global commercialization of its anticancer treatment Rivoceranib as it secured statistical significance in Phase 3 global clinical trials of the drug, according to the local biotech company, Sunday.
Baek Byung-yeul | 2022-05-15 16:23
Lotte seeks to acquire US CMO plant to enter bioindustry
Lotte seeks to acquire US CMO plant to enter bioindustry
Lotte Group is in the process of acquiring a bioindustry contract manufacturing (CMO) plant in the U.S., according to the investment banking industry, Thursday. The move comes after the conglomerate declared the bioindustry as its new growth engine. CMOs specialize in producing biopharmaceuticals developed by other companies.
Kim Hyun-bin | 2022-05-05 14:46
CHA Biotech's US subsidiary opens CDMO plant in Texas
CHA Biotech's US subsidiary opens CDMO plant in Texas
Matica Biotechnology, a U.S. affiliate of CHA Biotech, has opened a cell and gene therapy manufacturing facility in College Station, Texas, according to the cell therapeutics and stem cell developer affiliate of CHA Medical & Bio Group, Wednesday.
Lee Kyung-min | 2022-05-04 15:53
Osstem Implant posts record profits for Q1
Osstem Implant posts record profits for Q1
Osstem Implant posted a record operating profit for the first quarter, the dental equipment manufacturer said Friday.
Baek Byung-yeul | 2022-04-29 16:30
 1 234
Top 10 Stories
  • Afghanistan earthquake killed more than 1,000 [PHOTOS]
  • McDonald's, Burger King, KFC face bleak prospects of selling Korean units
  • Missing family's car discovered underwater in Wando
  • NongHyup Bank expands Dokdo-themed metaverse platform
  • Yoon arrives in Spain for NATO summit
  • Finance chief calls for corporate restraint on 'excessive' wage increases amid inflation woes
  • Korea on track to cut dependency on China for rare earths
  • Prosecution agrees to suspension of ex-President Lee's prison term
  • Yoon confident in his multilateral diplomacy debut
  • South Korea's new COVID-19 cases tick up amid pandemic slowdown
DARKROOM
  • Afghanistan earthquake killed more than 1,000 [PHOTOS]

    Afghanistan earthquake killed more than 1,000 [PHOTOS]

  • Divided America reacts to overturn of Roe vs. Wade [PHOTOS]

    Divided America reacts to overturn of Roe vs. Wade [PHOTOS]

  • Namaste: Yogis to celebrate International Yoga Day

    Namaste: Yogis to celebrate International Yoga Day

  • Poor hit harder by economic crisis

    Poor hit harder by economic crisis

  • Roland Garros 2022

    Roland Garros 2022

The Korea Times
CEO & Publisher : Oh Young-jin
Digital News Email : webmaster@koreatimes.co.kr
Tel : 02-724-2114
Online newspaper registration No : 서울,아52844
Date of registration : 2020.02.05
Masthead : The Korea Times
Copyright © koreatimes.co.kr. All rights reserved.
  • About Us
  • Introduction
  • History
  • Location
  • Media Kit
  • Contact Us
  • Products & Service
  • Subscribe
  • E-paper
  • Mobile Service
  • RSS Service
  • Content Sales
  • Policy
  • Privacy Statement
  • Terms of Service
  • 고충처리인
  • Youth Protection Policy
  • Code of Ethics
  • Copyright Policy
  • Family Site
  • Hankook Ilbo
  • Dongwha Group